No link found between IVF and ovarian cancer

According to a large population study in Denmark, presented at the European Society of Human Reproduction and Embryology meeting, there is no association between ovarian cancer and hormonal stimulation of the ovaries to assist reproduction.Medical Xpress
Source: Society for Endocrinology - Category: Endocrinology Source Type: news

Related Links:

PMID: 30243508 [PubMed - in process]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
More than 80 percent of people with identifiable genetic risk for breast, ovarian, prostate and pancreatic cancer are unaware of the situation, a study found.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
Emilee Garfield, 42, of Santa Barbara, California, was born with a rare form of cancer of the connective tissue and was later diagnosed with ovarian cancer in 2015.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Authors: David-West G, Ernlund A, Gadi A, Schneider RJ Abstract Platinum resistance is a major cause of treatment failure and mortality in epithelial ovarian cancer. mTORC1/2 inhibitors, which impair mRNA translation, can re-sensitize resistant ovarian cancer cells to platinum chemotherapy but the mechanism remains poorly described. Using platinum-resistant OVCAR-3 cells treated with the selective mTORC1/2 inhibitor INK128/MLN128, we conducted genome-wide transcription and translation studies and analyzed the effect on cell proliferation, AKT-mTOR signaling and cell survival, to determine whether carboplatin resist...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
ConclusionsOur study shows that Vav3.1 is not suited as a marker of cancer progression and/or treatment response in endometrial cancer. Feasibility and potential benefit of targeting Vav3.1 in endometrial cancer needs to be evaluated in future studies, proceeding from its clear, roughly ten-fold, induction in the malignant endometrium.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Despite frequently engaging with their healthcare providers, 8 out of 10 people with a cancer susceptibility gene don't know they are at risk of breast, ovarian, prostate and pancreatic cancers.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
September is Ovarian Cancer Awareness month, and this is my story. It is also the story shared by 249,000 women diagnosed annually worldwide and over 1 million immediate family members and caregivers. I learned of my mother’s ovarian cancer diagnosis over the phone — we were separated by 10,000 miles. What followed in the next 11 months were a roller coaster of challenges, hope, healing, prayers and acceptance. My mother was the rock of my life, and, after 11 months of fighting the battle o f…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
This study highlights the power of clinical cancer proteomics to identify targets for chemo- and immunotherapy and illuminate their biological roles.Graphical Abstract
Source: Cell - Category: Cytology Source Type: research
Authors: Ma Y, Xu Y, Li L Abstract Ovarian cancer is the most lethal gynecological malignancy worldwide and is one of the five leading causes of cancer-associated mortality in women. There is an urgent requirement to obtain a greater understanding of the molecular mechanism underlying ovarian cancer progression in order to identify novel drug targets and biomarkers. Secreted protein acidic and rich in cysteine-like protein 1 (SPARCL1) has been suggested as a candidate tumor suppressor in various types of human cancers. However, the potential role of SPARCL1 for ovarian cancer has not yet been clearly established. I...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
(Yale University) Genomic screening of more than 50,000 people shows that more than 80 percent of those who carry an identifiable genetic risk for breast, ovarian, prostate, and pancreatic cancer don't know it despite frequent interaction with the healthcare system.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Denmark Health | Endocrinology | Hormones | Ovarian Cancer | Ovaries | Reproduction Medicine | Study